Urgent Evaluation of Severe Menstrual Bleeding After IUD Insertion

Recognition of Abnormal Bleeding

Heavy or prolonged bleeding is uncommon with levonorgestrel‑releasing IUDs and should prompt clinical evaluation for underlying problems, according to CDC guidance. 1
In copper IUD users, heavy bleeding is more frequent during the first 3–6 months, but the presence of baseball‑sized clots indicates excessive blood loss that requires immediate assessment (CDC). 2
The CDC specifically recommends same‑day clinical evaluation when menstrual bleeding is severe after IUD placement, because it may signal complications rather than normal adjustment. [1][2]

Verify IUD position by checking that strings are present and of appropriate length to rule out displacement or malposition (CDC). [1][2]
Exclude pregnancy, including ectopic pregnancy, as a cause of abnormal bleeding (CDC). [1][2]
Screen for sexually transmitted infections, which can produce abnormal bleeding patterns (CDC). [1][2]
Evaluate for new pathologic uterine conditions such as polyps or fibroids that may explain the bleeding (CDC). [1][2]

A short course (5–7 days) of non‑steroidal anti‑inflammatory drugs (e.g., ibuprofen or mefenamic acid) can significantly reduce menstrual blood loss in IUD users (CDC). 2
Evidence from multiple studies shows NSAIDs lower blood loss by a measurable amount in copper IUD users (CDC). 2
Antifibrinolytic therapy with tranexamic acid may be considered, but safety data are limited and it is contraindicated in women with thrombotic risk (CDC). 1

Persistent severe bleeding despite appropriate medical therapy, when the patient finds it unacceptable, warrants removal or offering removal of the IUD (CDC). [1][2]
Confirmed IUD displacement or malposition should lead to removal of the device (CDC). 1
When an identified underlying condition (e.g., infection, uterine pathology) requires IUD removal for definitive treatment, the device should be removed (CDC). 1

Do not dismiss baseball‑sized clots as “normal adjustment bleeding.” While spotting and light bleeding are expected during the first 3–6 months, large clots represent excessive blood loss that mandates same‑day evaluation (CDC). [1][2]
Distinguishing expected minor bleeding (spotting, light flow) from pathological bleeding (large clots, soaking through protection) is essential for patient safety (CDC). 1

The Centers for Disease Control and Prevention recommends verifying proper IUD placement by checking for the presence of IUD strings, and considering underlying gynecological problems that may cause persistent bleeding, such as IUD displacement, sexually transmitted infections, pregnancy, and pathologic uterine conditions, in a patient with persistent vaginal bleeding 4 months after Mirena IUD placement 3, 4, 5
If an underlying gynecological problem is found, the American College of Obstetricians and Gynecologists suggests treating the identified condition or referring for appropriate care, with a strength of evidence classified as Level A, based on good and consistent scientific evidence 3, 5

The Centers for Disease Control and Prevention notes that unscheduled spotting or light bleeding is expected during the first 3-6 months of LNG-IUD use, with a median duration of 3-6 months, and this bleeding is generally not harmful and typically decreases with continued use, with approximately 50% of users experiencing amenorrhea or oligomenorrhea by 2 years 3, 5, 6
The American College of Obstetricians and Gynecologists recommends providing reassurance and education to patients about expected bleeding patterns, which has been shown to improve method continuation, with a strength of evidence classified as Level B, based on limited or inconsistent scientific evidence 3, 6, 7

If bleeding persists and is unacceptable to the patient, the Centers for Disease Control and Prevention suggests counseling on alternative contraceptive methods, with a strength of evidence classified as Level A, based on good and consistent scientific evidence 3, 5, 7